Hi, everyone. Welcome to the Jefferies London Healthcare Conference. I'm Shan Hama from the European Pharma and Biotech team at Jefferies, and I'm grateful to have with us today the CEO of Camurus, Fredrik Tiberg. Thank you very much for joining.
Sure.
Let's just get straight into it. You recently reported your strongest quarter to date. You had very robust revenue growth, you had very strong operating profit, and then also SEK 4.4 billion in cash. It's a pretty great place for a biopharma company to be. How would you frame the investment case for Camurus today?
Well, I think, in the sense we are unique that we have a very strong growing commercial business in our main area of substance use disorders or opioid dependence treatment. And we are now also expanding into two new indications, hopefully in the next coming year, also geographically, into endocrinology with acromegaly as our main target indication, and then also neuroendocrine tumors, based, of course, on the fact that we are going to receive good positive phase III results soon. So we have an exciting commercial franchise being built up with multiple legs. And on top of that, of course, we also have an expanding pipeline with programs in cardiometabolic areas, collaborations with key players in the metabolic space, and a lot of interesting things moving in the early pipeline as well.
Definitely. You sort of guided in your 3Q results that you expect revenue and operating profit to now be towards the upper half of your guided range. As we look into 2027, what are the biggest underlying drivers that investors should be looking out for, both on the top line and the bottom line?
Yeah, I mean, top line, of course, it will be the continued development in the opioid dependence treatment area and the expansion there, both in our own markets and also our partner in the U.S. And we see significant potential to continue to grow. On top of that, of course, we are starting to see the launches in Europe, in acromegaly, coming through and bearing fruit. So, that would be the second part, collaborations, potential milestones on top of that. So, there's multiple components in our coming years' top line. Bottom line, of course, we are continuing to drive revenue faster than we are accumulating costs, so hopefully we'll continue to strengthen the margins in line with our expectations.
Understood. If we move on to one of your key products, Buvidal, it had another record quarter in 3Q. You had volume growth that was very broad-based across several regions. What's driving the strength for Buvidal today, and how sustainable do you think that growth is into 2027?
I mean, ultimately, it's the medical need that we are fulfilling with the treatment, the long-acting weekly and monthly treatment of opioid dependence. So that's the ultimate driver, and the resistance we have is mainly in Europe in the financing side. So funding is one topic. But I think it's the in-market demand that is driving the business, and that's broadly driven across our geographies.
Very clear. You're now at around 81,000 patients treated and remain on track for 100,000 by the end of next year. That implies a sort of 3,000 to 4,000 cadence quarter- on- quarter. Where do you think the next roughly 20,000 patients will come from?
Again, I think it is a broad uptake across our markets. There are significant opportunities, and some of them will come through, but I think the broad uptake is across geographies, and the same geographies as grew this year, I think, mainly.
Understood. The U.K. is, of course, a key market for Buvidal. You mentioned that prison access appears to be improving, but in the community, some of that funding is a little bit slow to trickle down to the clinics. What is holding back the community uptake, and what specifically needs to change for that opportunity to accelerate on the commissioner side?
It is really on the outpatient side, it is funding coming down to the clinics, and also clinics prioritizing treatment over perhaps internal costs and so forth. So, we are in dialogue on all levels with all stakeholders, including government representatives, to make sure that funding comes through as conveniently as possible for our stakeholders out in the clinical setting.
Very clear.
But it's work across. What we have done, of course, and you might have seen, we just had a publication showing the considerable financial benefits we have seen and we have modeled with Buvidal. We had approximately GBP 140,000 in savings, in savings per year for people treated with Buvidal versus those untreated. So, that's a strong argument going forward, talking with the stakeholders.
Understood. If we move on to one of your other key markets, Australia, you have a very, very high market penetration in Australia. I think Buvidal's around 80% share. There's potentially another 3,000 to 4,000 patients that you could switch on from SUBLOCADE to Buvidal, because of course SUBLOCADE is exiting the market by the end of this year. How is that transfer progressing, and should we expect the majority, if not all, of those 3,000 to 4,000 patients to be on Buvidal by, say, 1H 2027?
First of all, I mean, when we're talking about market share, we have 80% of the long-acting market.
We have approximately over 30% of the overall treatment market in Australia, so that's still very strong. I think there is potential to continue to grow into that market, and when it comes to the 80%, obviously with our competitor leaving the market, we will grow into that to some extent. I think it is actually more than 3,000 to 4,000. It's more like 4,000 to 5,000 patients total. It depends on the capacity in the treatment system. We are working with the treatment providers, with their medical education and so forth, to facilitate the fast transfer, and hopefully we can catch a majority of those patients before end of Q4 or into Q1 next year.
Okay.
That is a growth driver, of course.
Okay. That is very clear. Now moving on to Brixadi, which is the product that is partnered in the U.S. with Braeburn. Braeburn has been investing quite heavily this year, actually, in sort of commercial and medical expansion efforts.
You mentioned that the benefits of this will likely be seen, or take a couple of quarters to be realized. When can we perhaps expect an acceleration of Brixadi from these efforts?
I think the impact of those changes and the expansion of the commercial organization, I mean, it involves quite a complex process with redistricting. Typically speaking, at least as I understand it may take a few quarters, maybe up to three to four quarters before you see the impact. I am expecting that to come in the first or second quarter, maybe already in the fourth quarter but remains to be seen.
Okay.
But it is an important effort and undertaking by our partner.
That is very clear. And of course, maybe you cannot give specifics here, but where is the bulk of the growth coming from with respect to channel for Brixadi, and could you perhaps give us a channel split for Brixadi?
That level of detail, I am sorry, I cannot provide.
That is fine.
But, I mean, the growth comes mainly from sublingual transitions.
I mean, 90% of the market there, or the market opportunity for us, is in the sublingual market, so that is where the growth is. Obviously, in this indication area, Medicaid has an important place, and it is the single biggest pathway. And that continues to be. We see good progress in the criminal justice system and also opportunities in telemedicine and other places,
Very clear. Longer- term, where do you think the U.S. long-acting injectable buprenorphine penetration can realistically reach? I think it is something like high single digits of the entire market. I do not think it has reached 10% yet, but what are the main barriers to further penetrate the sublingual population?
It is difficult to give an exact measure, but I would say that at this point, we are around 10% penetration of the market. I mean, it could absolutely grow up to 20%, and there is possibilities beyond that. It is very much related to the market access situation in the U.S. and also how the overall landscape develops. But I think the opportunities are there. It is execution and also a little bit about how the political landscape evolves.
Understood. Perhaps we could touch on the Supernus and Indivior merger, which closed very recently. Do you foresee any potential headwinds? Maybe that is a strong word, but do you foresee any headwinds from that merger, given that you have the muscle of Supernus and you also have the muscle of Indivior combined?
Well, it's very difficult to predict how that is going to evolve. I mean, there is both I think Indivior historically has been a very strong commercialization engine, and how that evolves and how it's impacted by the merger, I don't know, but it's certainly an interesting situation. I do believe that it's important to get more attention into this treatment area. The more investment we see, I think it's better for both parties, and it gives us further opportunities jointly. But it's not like I'm sleepless.
Understood. Perhaps if we move on to SORENTO now, which is arguably the most talked about catalyst, I think, in the biopharma space, at least from what I'm hearing from investors. You have this phase III study with data expected 1Q 2027. It's probably, I would argue, the biggest value driver for Camurus in the near- term.
As we approach the readout, what gives you confidence in a positive outcome for the study?
I mean, to be honest, I've been pretty confident since we invested in this. It's been a big investment and a big undertaking for us as a company. I think how the study has panned out and the fact that we are really super laser-focused on the performance of the study and the quality of the data coming out, I feel that we have the right assumptions in the study. There is nothing that indicates that it's going the wrong direction, and that feels confident, and that builds confidence for me.
Understood. Beyond statistical significance, what magnitude of PFS benefit would you regard as clinically meaningful enough to change physician behavior and actually see CAM2029 as a first-line regimen?
Yeah, the study is powered with a hazard ratio of 0.65, so that corresponds to a 35% improvement. Because of the fact that the PFS in these patient groups are pretty extended, they can be up to several years, the impact of a 35% improvement in terms of overall improvement, absolute improvement is rather large. We, I mean, across the range where we think we can establish statistical superiority, our feedback from physicians and payers is that that will also be regarded as clinically relevant superiority. We are quite safe on that side.
Okay. That's very clear. You've referenced around 38,000 metastatic NET patients actually receiving these drugs in the U.S. alone. If SORENTO is positive, how quickly would CAM2029 penetrate that population, and how quickly do you think physicians would be quick to adopt that regimen, based on your conversations with them?
Well, I mean, in this patient group, this is first-line treatment, and a new first-line treatment with established superiority. I believe there will be a quick transition. The two groups that we are looking at is the ones that are beginning treatment, so they have newly diagnosed, and that's more or less the group that we are having in the SORENTO trial, so diagnosed within the last six months. There is of the order 5,000 patients every year that are diagnosed in the U.S. with, and that is growing maybe up to 5,500 or so. I think that's really the low-hanging fruit for us, first of all. But then there is all the treatment, the rest of the population, the 32,000 or so that can be switched over. I think we'll see a good and fast uptake. It's difficult to predict exactly. Obviously, it will depend on the clinical outcomes and so forth, but I think the dynamics and the situation as it's standing now is looking good for a rapid uptake. We are not giving any guidance on that yet, though.
Understood. If we now move on to Oczyesa. On Oczyesa, the original manufacturing site has not yet been re-inspected. This is the one in Europe. Then you recently mentioned that you now have this U.S. secondary site, which demonstrated bioequivalence, and it's recently been inspected by FDA as well. What gives you confidence that i n this potentially extended review period, both sites will be compliant and inspected by FDA?
First of all, the first European site has undertaken all the corrections, has done all the CAPAs and so forth, so we believe they are in a good condition. In 2024, we invested and started to invest in a broader supply chain to secure future for the neuroendocrine indication and other things, and we are now ready to submit the U.S. manufacturer. We have all the data. We have done bioequivalence studies, et cetera. We are in a situation where we have two manufacturers that have performed all and that are in shape for an inspection. Then, we can't drive the FDA's schedule, so to avoid any further delays, we have decided, and we are in the process of submitting an amendment, and that could potentially, from the PDUFA date, result in up to a three-month extension of the review time.
We're expecting the approval to come somewhere from the current PDUFA date up to that extension time.
Understood. That is very clear. Perhaps if we touch on Oczyesa. In Germany, Oczyesa has already reached around 100 patients, or approximately 5% of patients receiving somatostatin receptor ligands. That, of course, doubled from 2Q. Does the early trajectory change your view of where penetration can ultimately reach? I believe the last sort of forecasted share you said was around double-digit penetration by the end of this year.
Yeah, we had, I mean, we grew in Germany with Oczyesa in acromegaly. We grew about almost 100%, 88% or so.
From Q2 to Q3, so we have a positive growth trajectory right now. What is limiting in here is that these patients, they come in to the physician maybe every three to six months, so that gives us a time lag that maybe prolongs the time, so to speak, between switches. Ultimately, we have a very positive feedback from the market, and I think we can grow up to significant numbers in terms of penetration. We will just see how quickly it can go from here on. We have positive feedback from the market and growing 88% quarter by quarter, hopefully a good trend.
Very clear. You have the U.K. awaiting broader formulary access. You have sort of Sweden, which is now launched, and then, of course, you have Canada planned for 2027. How should we think about the sequencing of Oczyesa geographically, and when can these additional markets be meaningful contributors?
I mean, current markets will be meaningful contributors on the overall top line next year. Canada, obviously, it takes at least a year to start to establish a full kind of launch sequence. We're expecting that to come towards the end of next year, and then we'll continue the geographic expansion. Hopefully, we'll be in the U.S. then with full force. We have the commercial setup already available and ready to go, and we are just going to introduce the sales force as quickly as possible once we have the approval secured.
Very clear. I think it's important to touch on this too. Have you seen any impact in terms of uptake of Oczyesa from PALSONIFY's entry in Europe?
Well, I haven't seen PALSONIFY entering the European market. I may be unaware of the situation right now, but we haven't seen any impact, at least that I know of. I will double-check.
Understood. Perhaps we just touch on obesity as well. Of course, you have CAM2056, which is your once-monthly Wegovy. It's currently in a phase IIb study, which is underway. The main questions I get from investors about this program is, firstly, why are you pursuing a program, CAM2056? Two, would you do phase III alone? Would you commercialize?
Yeah, I mean, the reason we are pursuing it is because we see a very big opportunity, and once-monthly dosing is an interesting opportunity in this competitive space. That's, I think, the starting point. We performed a phase Ib study, which showed very positive weight reduction, but without compromising tolerability versus the current weekly product. I think that was a strong data set. We had 10% weight reduction in 12 weeks of treatment versus approximately 5% for the current treatment regimen or the comparator, Wegovy. Now we are doing a phase IIb study to establish the long-term treatment effects alongside increases in dosing, and I think that's a very interesting data set.
We kept this asset because we have also potentially interest in the substance use disorder area, and because it was the only compound that was available with a patent life that was compatible with our development program. We have, as you know, also currently three programs in this space ongoing together with Lilly. So, I think it's a complementary story there.
Understood.
Interesting.
Would you do phase III alone? Is that a possibility, or would you prefer partnering?
We haven't excluded the opportunity of doing that. We are preparing for it. We are setting up the final product configuration. We have a new autoinjector pen developed with a partner. So, we have everything going, then we'll see how the landscape looks at the end of next year. The phase IIb data are expected in the first half of 2028, so somewhere in that timeframe, we will be ready to move into the next phase.
Very clear. Perhaps if we touch on your financial position. So, you have a very good cash position, no debt. How should we think about how much capital you are prepared to invest externally in new assets, new companies potentially, versus reinvesting in your existing pipeline?
I mean, our priority is organic growth. We have good financial flexibility with SEK 4.4 billion in cash and no debt, as you said. We are also looking intensively, increasingly focused on business development efforts, complementary assets, commercial, pre-commercial stage in the areas that we are currently focusing on, as well as earlier phase opportunities in phase II up to phase III, I would say, proof of concept. We will see how that work progresses. We have a big, competent team working, so we will see how it emerges.
Understood. Could you perhaps remind us of your firepower? How much would you be willing to spend for one particular deal?
We are not disclosing that specifically, but we definitely can go up to billion-dollar deals if we prioritize the development.
That is very clear. Thank you. Any questions from the audience? No? Do you have any closing remarks?
Well, no, I think, yes, I do certainly have closing remarks. I mean, I hope you see that we have a very interesting business ongoing with the opioid dependence development going very well and new indication areas coming up in the next year, and some near-term milestones. We have, of course, the approval in acromegaly, that approval decision, I should say, in acromegaly coming, and not the least then the phase III results from the SORENTO trial, which are potentially going to be transformative for Camurus in the coming year. So, it is a very interesting time for us.
Thank you very much. Thanks, Fredrik.
Thank you so much.
Thanks for joining.